Piperaquine is a bis-quinoline compound that inhibits the ex vivo growth of P. falciparum isolates from malaria-infected patients with IC50s ranging from 11.8-217.3 nM.1 Formulations containing piperaquine have been used in combination with artemisinin for the treatment of malaria in HIV-1-positive populations.2,3,4
1.Akoachere, M., Buchholz, K., Fischer, E., et al.In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisininsAntimicrob. Agents Chemother.49(11)4592-4597(2005) 2.Askling, H.H., Bruneel, F., Burchard, G., et al.Management of imported malaria in EuropeMalar. J.11(2012) 3.Henrich, P.P., O'Brien, C., Sáenz, F.E., et al.Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent modelAntimicrob. Agents Chemother.58(1)183-195(2014) 4.Pascual, A., Parola, P., Benoit-Vical, F., et al.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparumMalar. J.11(2012)